<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217668</url>
  </required_header>
  <id_info>
    <org_study_id>HR002 Provocation</org_study_id>
    <nct_id>NCT04217668</nct_id>
  </id_info>
  <brief_title>Headache Provocation of People Who Are Unable to Have Headache</brief_title>
  <official_title>Pain Perception, Headache Provocation and Multiomics of People Who Are Unable to Have Headache</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Headaches are extremely common illnesses with a combined lifetime prevalence of 90-99% in&#xD;
      Europe. Despite this high prevalence, there are persons who have never, in their whole life,&#xD;
      encountered a headache.&#xD;
&#xD;
      The aim of the study is to identify factors that protect against headache by studying&#xD;
      headache after provocation in people who never have had a headache (headache resistant)&#xD;
      versus non-resistant controls.&#xD;
&#xD;
      The investigators will use isosorbide mononitrate as a pharmacological trigger of headache.&#xD;
      The provocation is performed by investigators who are blinded to the grouping of the&#xD;
      participants.&#xD;
&#xD;
      The investigators hope to contribute with novelty to the current understanding of headache&#xD;
      pathophysiology and development of more efficient treatment of headache.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Actual">March 12, 2020</completion_date>
  <primary_completion_date type="Actual">March 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Blinded case-control study</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The investigators are blinded to the case-control grouping of the participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of headache intensity</measure>
    <time_frame>5 hours</time_frame>
    <description>Area under the curve of headache intensity from 0 - 5 hours post tablet administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of headache intensity</measure>
    <time_frame>12 hours</time_frame>
    <description>Area under the curve of headache intensity from 0 - 12 hours post tablet administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Headache</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Isosorbide mononitrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cases and controls both receive one tablet ImdurÂ® 60 mg (isosorbide mononitrate) on the study day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosorbide Mononitrate 60 MG</intervention_name>
    <description>1 tablet Isosorbide Mononitrate 60 mg administrated orally.</description>
    <arm_group_label>Isosorbide mononitrate</arm_group_label>
    <other_name>Imdur</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Headache resistant and non-resistant male participants from the Danish Blood Donor&#xD;
             Study.&#xD;
&#xD;
          -  Weight: 45 kg to 95 kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Daily consumption of any medication.&#xD;
&#xD;
          -  Consumption of any medication less than 12 hours prior to the study day.&#xD;
&#xD;
          -  Headache on the study day or 48 hours prior to the study day.&#xD;
&#xD;
          -  Amnestic or clinical signs of hypertension (systolic blood pressure &gt;150 mmHg and/or&#xD;
             diastolic blood pressure &gt;100 mmHg) or hypotension (systolic blood pressure &lt;90 mmHg&#xD;
             and/or diastolic blood pressure &lt;50 mmHg).&#xD;
&#xD;
          -  Any severe cardiovascular disease, including cerebrovascular illness.&#xD;
&#xD;
          -  Amnestic or clinical signs of current mental illness.&#xD;
&#xD;
          -  Amnestic or clinical signs of current substance or drug abuse.&#xD;
&#xD;
          -  Amnestic or clinical signs of any illness the responsible doctor considers relevant&#xD;
             for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jes Olesen, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Danish Headache Center</name>
      <address>
        <city>Glostrup</city>
        <state>Region H</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Isa Amalie Olofsson</investigator_full_name>
    <investigator_title>Medical Doctor, PhD student</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

